All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cancer type (metastatic) cancer type (recurrent) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) PDL1 (TPS >50%) PDL1 < 25% PDL1 >25% smoker (current or former) smoker (Current) smoker (Former) smoker (never) stage III (locally advanced) stage IIIa stage IIIb stage IV (metastatic) Teff high Teff low
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), immune chekpoint inhibitors vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.63 [0.42; 0.94]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.80 [0.61; 1.05]
CheckMate 026 (PDL1>1%), 2016 1.07 [0.86; 1.33]
CheckMate 026 (PDL1>5%), 2016 1.02 [0.80; 1.30]
CheckMate 9LA, 2021 0.69 [0.55; 0.87]
EMPOWER lung1 (all population), 2021 0.68 [0.53; 0.87]
EMPOWER lung1 (PDL1>50%), 2021 0.57 [0.42; 0.77]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.83 [0.65; 1.06]
IMpower-110 (TC2/3 or IC2/3), 2020 0.72 [0.52; 0.99]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.40; 0.88]
KEYNOTE-024 (PDL1>50%), 2016 0.60 [0.41; 0.88]
KEYNOTE-042 (PDL1>1%), 2019 0.81 [0.71; 0.93]
KEYNOTE-042 (PDL1>20%), 2019 0.77 [0.64; 0.92]
KEYNOTE-042 (PDL1>50%), 2019 0.69 [0.56; 0.85]
KEYNOTE-189, 2018 0.49 [0.38; 0.64]
KEYNOTE-407, 2018 0.64 [0.49; 0.84]
MYSTIC (D ; all population), 2020 0.96 [0.81; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.76 [0.56; 1.03]
MYSTIC (DT ; all population), 2020 0.94 [0.80; 1.11]
MYSTIC (DT ; PDL1>25%), 2020 0.85 [0.61; 1.18]
ORIENT-11, 2020 0.61 [0.40; 0.93]
0.75 [0.69 ; 0.82 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 21 62% 11,169 moderate critical deaths (OS) (extension)detailed results CheckMate 9LA, 2021 0.66 [0.55; 0.80]
IMpower-110 (TC3 or IC3), 2020 0.76 [0.53; 1.08]
KEYNOTE-024 (PDL1>50%), 2016 0.62 [0.48; 0.81]
KEYNOTE-042 (PDL1>1%), 2019 0.80 [0.71; 0.90]
KEYNOTE-042 (PDL1>20%), 2019 0.75 [0.64; 0.88]
KEYNOTE-042 (PDL1>50%), 2019 0.98 [0.82; 1.18]
KEYNOTE-189, 2018 0.56 [0.45; 0.70]
0.73 [0.64 ; 0.83 ] CheckMate 9LA, 2021, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 7 70% 4,536 moderate not evaluable PFS (extension)detailed results CheckMate 9LA, 2021 0.68 [0.57; 0.82]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.72 [0.60; 0.86]
IMpower-110 (TC2/3 or IC2/3), 2020 0.64 [0.50; 0.82]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.43; 0.81]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.39; 0.65]
KEYNOTE-042 (PDL1>1%), 2019 1.05 [0.93; 1.18]
KEYNOTE-042 (PDL1>20%), 2019 0.95 [0.82; 1.10]
KEYNOTE-042 (PDL1>50%), 2019 0.85 [0.71; 1.01]
KEYNOTE-189, 2018 0.48 [0.40; 0.58]
0.70 [0.58 ; 0.85 ] CheckMate 9LA, 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 9 90% 5,418 moderate serious progression or deaths (PFS)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.71 [0.49; 1.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.77 [0.59; 1.01]
CheckMate 026 (PDL1>1%), 2016 1.17 [0.95; 1.44]
CheckMate 026 (PDL1>5%), 2016 1.15 [0.91; 1.45]
CheckMate 9LA, 2021 0.70 [0.57; 0.86]
EMPOWER lung1 (all population), 2021 0.59 [0.49; 0.72]
EMPOWER lung1 (PDL1>50%), 2021 0.54 [0.43; 0.68]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.77 [0.63; 0.94]
IMpower-110 (TC2/3 or IC2/3), 2020 0.67 [0.52; 0.87]
IMpower-110 (TC3 or IC3), 2020 0.63 [0.45; 0.88]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.37; 0.68]
KEYNOTE-042 (PDL1>1%), 2019 1.07 [0.94; 1.21]
KEYNOTE-042 (PDL1>20%), 2019 0.94 [0.80; 1.11]
KEYNOTE-042 (PDL1>50%), 2019 0.81 [0.67; 0.98]
KEYNOTE-189, 2018 0.52 [0.43; 0.63]
KEYNOTE-407, 2018 0.56 [0.45; 0.70]
MYSTIC (D ; PDL1>25%), 2020 0.87 [0.59; 1.29]
MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.72; 1.53]
ORIENT-11, 2020 0.48 [0.36; 0.64]
0.74 [0.64 ; 0.84 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 19 85% 9,679 moderate low objective responses (ORR)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 3.87 [1.55; 9.69]
ARCTIC (DT ; study B ; PDL1<25%), 2020 2.43 [1.05; 5.65]
CheckMate 026 (PDL1>5%), 2016 0.70 [0.46; 1.06]
CheckMate 9LA, 2021 1.80 [1.31; 2.48]
EMPOWER lung1 (all population), 2021 2.21 [1.58; 3.10]
EMPOWER lung1 (PDL1>50%), 2021 2.53 [1.32; 4.85]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.89 [0.62; 1.27]
IMpower-110 (TC2/3 or IC2/3), 2020 0.94 [0.59; 1.50]
IMpower-110 (TC3 or IC3), 2020 1.55 [0.86; 2.79]
KEYNOTE-024 (PDL1>50%), 2016 2.11 [1.31; 3.39]
KEYNOTE-042 (PDL1>1%), 2019 1.04 [0.81; 1.33]
KEYNOTE-042 (PDL1>20%), 2019 1.24 [0.92; 1.66]
KEYNOTE-042 (PDL1>50%), 2019 1.39 [0.99; 1.94]
KEYNOTE-189, 2018 3.88 [2.61; 5.79]
KEYNOTE-407, 2018 2.20 [1.57; 3.09]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.43]
MYSTIC (DT ; PDL1>25%), 2020 0.87 [0.55; 1.37]
ORIENT-11, 2020 2.54 [1.63; 3.97]
1.55 [1.24 ; 1.95 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>5%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 18 82% 9,138 moderate low objective responses (ORR) (extension)detailed results IMpower-110 (TC3 or IC3), 2020 1.68 [0.94; 3.01]
KEYNOTE-024 (PDL1>50%), 2016 1.89 [1.19; 3.02]
KEYNOTE-042 (PDL1>1%), 2019 1.03 [0.81; 1.32]
KEYNOTE-042 (PDL1>20%), 2019 1.21 [0.90; 1.62]
KEYNOTE-042 (PDL1>50%), 2019 1.35 [0.96; 1.88]
KEYNOTE-189, 2018 3.84 [2.58; 5.70]
1.62 [1.11 ; 2.38 ] IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 6 85% 3,817 moderate not evaluable AE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.24 [0.01; 5.43]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.59 [0.20; 1.69]
EMPOWER lung1 (all population), 2021 0.18 [0.12; 0.27]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.52 [0.27; 1.01]
KEYNOTE-189, 2018 4.04 [0.36; 44.82]
KEYNOTE-407, 2018 1.20 [0.36; 3.96]
MYSTIC (D ; all population), 2020 0.59 [0.31; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.42 [0.14; 1.22]
MYSTIC (DT ; all population), 2020 0.51 [0.27; 0.96]
MYSTIC (DT ; PDL1>25%), 2020 0.43 [0.15; 1.24]
ORIENT-11, 2020 1.02 [0.03; 30.46]
0.49 [0.31 ; 0.77 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 11 59% 5,290 moderate critical AE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.36 [0.18; 0.75]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.70 [0.43; 1.12]
EMPOWER lung1 (all population), 2021 0.19 [0.13; 0.29]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.39 [0.27; 0.55]
KEYNOTE-189, 2018 1.03 [0.73; 1.45]
KEYNOTE-407, 2018 0.99 [0.70; 1.39]
MYSTIC (D ; all population), 2020 0.81 [0.60; 1.10]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.41]
MYSTIC (DT ; all population), 2020 1.02 [0.76; 1.37]
MYSTIC (DT ; PDL1>25%), 2020 0.86 [0.56; 1.35]
ORIENT-11, 2020 1.13 [0.74; 1.73]
0.69 [0.50 ; 0.95 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 11 87% 5,290 moderate low AE leading to death (grade 5)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 3.27 [0.63; 16.86]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.41 [0.52; 3.82]
EMPOWER lung1 (all population), 2021 1.24 [0.46; 3.38]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.39; 2.15]
KEYNOTE-189, 2018 1.13 [0.56; 2.28]
KEYNOTE-407, 2018 1.31 [0.69; 2.49]
MYSTIC (D ; all population), 2020 0.82 [0.38; 1.75]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.20; 2.86]
MYSTIC (DT ; all population), 2020 2.19 [1.17; 4.11]
MYSTIC (DT ; PDL1>25%), 2020 3.45 [1.24; 9.59]
ORIENT-11, 2020 0.31 [0.11; 0.90]
1.23 [0.87 ; 1.75 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 11 42% 5,290 moderate low AE leading to treatment discontinuation (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.63 [0.24; 1.67]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.09 [0.58; 2.03]
EMPOWER lung1 (all population), 2021 1.62 [0.82; 3.21]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.34 [0.19; 0.61]
KEYNOTE-189, 2018 2.19 [1.31; 3.65]
KEYNOTE-407, 2018 2.28 [1.45; 3.61]
MYSTIC (D ; all population), 2020 0.72 [0.47; 1.12]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.38; 1.46]
MYSTIC (DT ; all population), 2020 1.43 [0.97; 2.10]
MYSTIC (DT ; PDL1>25%), 2020 1.63 [0.91; 2.93]
ORIENT-11, 2020 0.70 [0.31; 1.55]
1.08 [0.75 ; 1.55 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 11 77% 5,290 moderate low AE leading to treatment discontinuation (grade 3-4)detailed results KEYNOTE-189, 2018 2.04 [1.16; 3.59]
KEYNOTE-407, 2018 2.09 [1.28; 3.39]
MYSTIC (D ; all population), 2020 1.10 [0.64; 1.89]
MYSTIC (DT ; all population), 2020 2.14 [1.32; 3.47]
ORIENT-11, 2020 0.64 [0.26; 1.56]
1.58 [1.08 ; 2.31 ] KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 5 56% 3,006 low not evaluable SAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.73 [0.81; 3.73]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.76 [1.04; 2.99]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.99 [0.68; 1.44]
MYSTIC (D ; PDL1>25%), 2020 1.22 [0.77; 1.94]
MYSTIC (DT ; PDL1>25%), 2020 1.93 [1.22; 3.04]
1.42 [1.07 ; 1.88 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; PDL1>25%), 2020 5 39% 1,587 moderate not evaluable STRAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.33; 3.10]
CheckMate 026 (PDL1>1%), 2016 0.93 [0.60; 1.46]
CheckMate 9LA, 2021 1.94 [1.36; 2.76]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.50 [0.29; 0.85]
KEYNOTE-024 (PDL1>50%), 2016 1.05 [0.60; 1.82]
MYSTIC (D ; all population), 2020 0.56 [0.35; 0.90]
MYSTIC (D ; PDL1>25%), 2020 0.38 [0.18; 0.77]
MYSTIC (DT ; all population), 2020 1.52 [1.03; 2.24]
MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.59; 1.87]
0.90 [0.62 ; 1.31 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 9 79% 4,289 moderate not evaluable STRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.82 [0.50; 1.33]
CheckMate 9LA, 2021 1.95 [1.33; 2.84]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.55; 1.72]
MYSTIC (D ; all population), 2020 0.48 [0.28; 0.84]
MYSTIC (DT ; all population), 2020 1.43 [0.92; 2.21]
1.04 [0.64 ; 1.67 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 5 80% 2,985 moderate serious TRAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.19 [0.08; 0.46]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.39 [0.22; 0.69]
CheckMate 026 (PDL1>1%), 2016 0.20 [0.12; 0.34]
CheckMate 9LA, 2021 1.55 [0.94; 2.55]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.27 [0.18; 0.40]
KEYNOTE-024 (PDL1>50%), 2016 0.31 [0.16; 0.58]
KEYNOTE-042 (PDL1>1%), 2019 0.19 [0.14; 0.26]
MYSTIC (D ; all population), 2020 0.24 [0.17; 0.34]
MYSTIC (D ; PDL1>25%), 2020 0.21 [0.12; 0.38]
MYSTIC (DT ; all population), 2020 0.31 [0.22; 0.44]
MYSTIC (DT ; PDL1>25%), 2020 0.17 [0.09; 0.30]
0.29 [0.20 ; 0.41 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 11 83% 5,823 moderate low TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.13 [0.05; 0.36]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.49 [0.29; 0.84]
CheckMate 026 (PDL1>1%), 2016 0.21 [0.14; 0.31]
CheckMate 9LA, 2021 1.44 [1.06; 1.94]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.19 [0.12; 0.29]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.20; 0.51]
KEYNOTE-042 (PDL1>1%), 2019 0.30 [0.23; 0.39]
MYSTIC (D ; all population), 2020 0.34 [0.24; 0.49]
MYSTIC (D ; PDL1>25%), 2020 0.36 [0.22; 0.61]
MYSTIC (DT ; all population), 2020 0.55 [0.39; 0.77]
MYSTIC (DT ; PDL1>25%), 2020 0.36 [0.22; 0.60]
0.36 [0.24 ; 0.54 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 11 91% 5,823 moderate low TRAE leading to death (grade 5)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 9LA, 2021 1.14 [0.38; 3.43]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.03; 3.11]
KEYNOTE-042 (PDL1>1%), 2019 0.90 [0.42; 1.92]
KEYNOTE-407, 2018 1.70 [0.61; 4.75]
MYSTIC (D ; all population), 2020 0.63 [0.11; 3.82]
MYSTIC (D ; PDL1>25%), 2020 0.95 [0.06; 15.32]
MYSTIC (DT ; all population), 2020 1.91 [0.47; 7.71]
MYSTIC (DT ; PDL1>25%), 2020 0.94 [0.06; 15.13]
1.06 [0.68 ; 1.66 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 9LA, 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 11 0% 5,851 moderate low TRAE leading to discontinuation (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.24; 4.26]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.81 [0.81; 4.05]
CheckMate 026 (PDL1>1%), 2016 0.70 [0.41; 1.20]
CheckMate 9LA, 2021 3.18 [1.94; 5.19]
KEYNOTE-024 (PDL1>50%), 2016 0.64 [0.29; 1.44]
KEYNOTE-042 (PDL1>1%), 2019 0.95 [0.64; 1.39]
MYSTIC (D ; all population), 2020 0.55 [0.31; 0.99]
MYSTIC (D ; PDL1>25%), 2020 0.47 [0.21; 1.04]
MYSTIC (DT ; all population), 2020 1.47 [0.92; 2.35]
MYSTIC (DT ; PDL1>25%), 2020 1.04 [0.54; 2.03]
1.02 [0.69 ; 1.50 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 10 75% 5,274 moderate low TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.24 [0.64; 2.40]
CheckMate 9LA, 2021 3.48 [2.00; 6.05]
KEYNOTE-024 (PDL1>50%), 2016 0.86 [0.32; 2.29]
KEYNOTE-042 (PDL1>1%), 2019 1.09 [0.71; 1.66]
MYSTIC (D ; all population), 2020 1.28 [0.60; 2.75]
MYSTIC (DT ; all population), 2020 2.95 [1.51; 5.78]
1.62 [1.01 ; 2.61 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 70% 4,236 moderate not evaluable Acute kidney injury TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.61 [0.14 ; 17.97 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020 2 0% 408 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
CheckMate 9LA, 2021 7.88 [0.41; 149.53]
KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
KEYNOTE-189, 2018 0.50 [0.03; 8.00]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
2.37 [0.73 ; 7.72 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 9LA, 2021, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 7 0% 4,417 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.35 [0.06 ; 2.07 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 4 0% 3,225 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.08 [0.00; 1.41]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.21 [0.02; 2.02]
CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.13]
CheckMate 9LA, 2021 0.37 [0.22; 0.63]
KEYNOTE-024 (PDL1>50%), 2016 0.08 [0.02; 0.28]
KEYNOTE-042 (PDL1>1%), 2019 0.04 [0.02; 0.12]
MYSTIC (D ; all population), 2020 0.01 [0.00; 0.19]
MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.19]
0.06 [0.02 ; 0.19 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 8 76% 4,644 moderate serious Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.97 [0.02 ; 48.81 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Asthenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.25 [0.01; 5.61]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
CheckMate 026 (PDL1>1%), 2016 0.12 [0.01; 2.31]
CheckMate 9LA, 2021 0.36 [0.09; 1.37]
KEYNOTE-042 (PDL1>1%), 2019 0.29 [0.08; 1.05]
MYSTIC (D ; all population), 2020 0.12 [0.01; 0.94]
MYSTIC (DT ; all population), 2020 0.06 [0.00; 1.01]
0.25 [0.12 ; 0.52 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 7 0% 4,340 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
KEYNOTE-024 (PDL1>50%), 2016 0.49 [0.02; 14.58]
0.98 [0.09 ; 10.85 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016 2 0% 834 moderate not evaluable Colitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
ARCTIC (DT ; study B ; PDL1<25%), 2020 3.86 [0.19; 77.90]
CheckMate 9LA, 2021 9.87 [0.54; 181.39]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-024 (PDL1>50%), 2016 3.93 [0.18; 87.97]
KEYNOTE-042 (PDL1>1%), 2019 3.89 [0.43; 34.87]
KEYNOTE-189, 2018 3.01 [0.15; 60.33]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
3.96 [1.54 ; 10.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 10 0% 5,967 moderate low Constipation TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 9LA, 2021 0.97 [0.02; 49.27]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
MYSTIC (D ; all population), 2020 0.48 [0.02; 14.24]
MYSTIC (DT ; all population), 2020 0.47 [0.02; 14.16]
0.69 [0.17 ; 2.76 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 7 0% 4,361 moderate serious Decreased appetite TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.09; 4.55]
CheckMate 026 (PDL1>1%), 2016 0.24 [0.03; 2.19]
CheckMate 9LA, 2021 0.97 [0.24; 3.93]
KEYNOTE-024 (PDL1>50%), 2016 0.12 [0.01; 2.27]
KEYNOTE-042 (PDL1>1%), 2019 0.53 [0.18; 1.60]
MYSTIC (D ; all population), 2020 0.24 [0.03; 2.13]
MYSTIC (DT ; all population), 2020 0.95 [0.24; 3.82]
0.56 [0.31 ; 1.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 8 0% 4,644 moderate not evaluable Dermatitis acneiform TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.40 [0.24 ; 8.12 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 4 0% 2,355 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 3.24 [0.37; 28.15]
CheckMate 026 (PDL1>1%), 2016 0.59 [0.14; 2.48]
CheckMate 9LA, 2021 7.06 [1.59; 31.30]
EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
KEYNOTE-024 (PDL1>50%), 2016 3.00 [0.60; 15.11]
KEYNOTE-042 (PDL1>1%), 2019 4.87 [0.57; 41.77]
MYSTIC (D ; all population), 2020 0.95 [0.13; 6.81]
MYSTIC (DT ; all population), 2020 4.35 [0.93; 20.28]
ORIENT-11, 2020 0.49 [0.01; 24.91]
2.24 [1.19 ; 4.20 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 10 3% 5,738 moderate low Dysgeusia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.98 [0.06 ; 15.72 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016 2 0% 834 moderate not evaluable Dyspepsia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 2.56 [0.11; 57.33]
2.56 [0.11 ; 57.33 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Fatigue TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.47 [0.10; 2.13]
CheckMate 026 (PDL1>1%), 2016 0.20 [0.06; 0.71]
CheckMate 9LA, 2021 3.97 [0.84; 18.81]
KEYNOTE-024 (PDL1>50%), 2016 0.38 [0.07; 2.00]
KEYNOTE-042 (PDL1>1%), 2019 0.36 [0.09; 1.36]
MYSTIC (D ; all population), 2020 0.81 [0.27; 2.45]
MYSTIC (DT ; all population), 2020 1.09 [0.39; 3.03]
0.65 [0.35 ; 1.22 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 8 36% 4,644 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.08 [0.00; 1.41]
CheckMate 9LA, 2021 1.38 [0.60; 3.15]
0.46 [0.03 ; 7.18 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 9LA, 2021 2 71% 832 moderate not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.19 [0.36; 3.94]
1.19 [0.36 ; 3.94 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.92 [0.20; 18.73]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 11.47 [1.48; 88.87]
KEYNOTE-042 (PDL1>1%), 2019 13.68 [0.77; 241.54]
KEYNOTE-189, 2018 4.02 [0.21; 76.41]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
4.95 [1.86 ; 13.14 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 8 0% 4,956 moderate not evaluable Hypersensitivity TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Hypertension TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.11; 14.23]
1.27 [0.11 ; 14.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
ORIENT-11, 2020 0.49 [0.01; 24.91]
0.97 [0.29 ; 3.23 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 10 0% 5,657 moderate critical Hypophysitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.76 [0.43 ; 7.22 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 3,889 moderate serious Hypothyroidism TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 9LA, 2021 1.95 [0.07; 58.39]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
MYSTIC (D ; all population), 2020 3.83 [0.17; 85.25]
MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.59 [0.57 ; 4.43 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 12 0% 6,894 moderate critical Increase AST TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.35; 10.63]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.66 [0.45 ; 6.18 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, EMPOWER lung1 (all population), 2021, KEYNOTE-042 (PDL1>1%), 2019, ORIENT-11, 2020 4 0% 2,628 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.04; 10.24]
CheckMate 026 (PDL1>1%), 2016 3.51 [0.72; 17.07]
CheckMate 9LA, 2021 2.46 [0.47; 12.75]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
KEYNOTE-042 (PDL1>1%), 2019 1.75 [0.58; 5.26]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.95 [0.94 ; 4.04 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, KEYNOTE-042 (PDL1>1%), 2019, ORIENT-11, 2020 6 0% 3,865 moderate not evaluable Increased lipase level TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 9LA, 2021 7.55 [2.24; 25.47]
5.43 [1.81 ; 16.31 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 9LA, 2021 3 0% 1,115 moderate not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.16 [0.02; 1.33]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
0.46 [0.12 ; 1.73 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 6 0% 3,119 moderate serious Leucopenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.16 [0.01; 3.32]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.10 [0.01; 2.08]
CheckMate 026 (PDL1>1%), 2016 0.05 [0.00; 0.92]
KEYNOTE-042 (PDL1>1%), 2019 0.05 [0.00; 0.82]
0.08 [0.02 ; 0.34 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 2019 4 0% 2,189 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
CheckMate 9LA, 2021 4.93 [0.57; 42.41]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
3.26 [0.66 ; 16.22 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021 3 0% 1,934 moderate not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
0.98 [0.02 ; 49.83 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.94 [0.06 ; 57.80 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.94 [0.06 ; 57.80 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Myositis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
0.68 [0.07 ; 6.51 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 2018 3 0% 1,194 moderate not evaluable Nausea TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.25 [0.01; 5.61]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 026 (PDL1>1%), 2016 0.19 [0.02; 1.67]
CheckMate 9LA, 2021 1.63 [0.39; 6.89]
KEYNOTE-024 (PDL1>50%), 2016 0.16 [0.01; 3.21]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
MYSTIC (D ; all population), 2020 0.08 [0.00; 1.41]
MYSTIC (DT ; all population), 2020 0.16 [0.02; 1.30]
0.31 [0.12 ; 0.77 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 8 12% 4,644 moderate serious Nephritis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 6.06 [0.34; 109.04]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
1.93 [0.46 ; 8.10 ] EMPOWER lung1 (all population), 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 4,303 moderate serious Neutropenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.09 [0.01; 1.76]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.03 [0.00; 0.45]
CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.25]
CheckMate 9LA, 2021 0.71 [0.41; 1.24]
KEYNOTE-024 (PDL1>50%), 2016 0.02 [0.00; 0.35]
KEYNOTE-042 (PDL1>1%), 2019 0.02 [0.00; 0.14]
MYSTIC (D ; all population), 2020 0.02 [0.00; 0.18]
MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.20]
0.04 [0.01 ; 0.22 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 8 82% 4,644 moderate serious Pancreatitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 2.56 [0.11; 57.33]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
1.87 [0.35 ; 9.94 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 4 0% 2,445 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 1.76]
0.44 [0.06 ; 3.02 ] CheckMate 026 (PDL1>1%), 2016, EMPOWER lung1 (all population), 2021, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,478 moderate not evaluable Peripheral oedema TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
1.14 [0.09 ; 14.91 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016 2 0% 813 moderate not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 0.08 [0.00; 1.43]
0.08 [0.00 ; 1.43 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.06; 16.62]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
0.87 [0.09 ; 8.46 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020 2 0% 408 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 6.52 [0.35; 120.50]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-024 (PDL1>50%), 2016 3.97 [0.44; 35.97]
KEYNOTE-042 (PDL1>1%), 2019 20.97 [2.81; 156.36]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
MYSTIC (D ; all population), 2020 3.85 [0.43; 34.59]
MYSTIC (DT ; all population), 2020 7.74 [0.96; 62.17]
ORIENT-11, 2020 0.98 [0.09; 10.96]
2.85 [1.42 ; 5.71 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 10 1% 5,657 moderate low Pruritic rash TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Pruritus TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
CheckMate 9LA, 2021 5.89 [0.29; 118.02]
KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.41 [0.37 ; 5.37 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 7 0% 4,612 moderate serious Pyrexia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.32 [0.01; 9.50]
CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.50 [0.06 ; 3.92 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016 3 0% 1,117 moderate not evaluable Rash TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.06; 16.62]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.31 [0.03; 3.50]
CheckMate 026 (PDL1>1%), 2016 1.98 [0.18; 21.94]
CheckMate 9LA, 2021 11.88 [0.66; 213.53]
EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
MYSTIC (DT ; all population), 2020 0.95 [0.06; 15.23]
ORIENT-11, 2020 0.16 [0.02; 1.56]
1.36 [0.62 ; 2.97 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 10 0% 5,983 moderate low Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
1.97 [0.07 ; 59.09 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 12.07 [0.67; 217.19]
12.07 [0.67 ; 217.19 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 12.12 [0.67; 218.98]
KEYNOTE-042 (PDL1>1%), 2019 10.81 [1.39; 83.96]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
3.88 [0.61 ; 24.61 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 3 62% 2,162 moderate not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 5.00 [0.58; 43.09]
5.00 [0.58 ; 43.09 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
KEYNOTE-024 (PDL1>50%), 2016 0.24 [0.01; 5.39]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.74 [0.16 ; 3.42 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 5 0% 2,493 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.16 [0.01; 3.50]
CheckMate 026 (PDL1>1%), 2016 0.04 [0.01; 0.31]
CheckMate 9LA, 2021 1.09 [0.44; 2.70]
KEYNOTE-024 (PDL1>50%), 2016 0.06 [0.00; 1.02]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 0.75]
MYSTIC (D ; all population), 2020 0.03 [0.00; 0.42]
MYSTIC (DT ; all population), 2020 0.03 [0.00; 0.42]
0.10 [0.02 ; 0.43 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 7 70% 4,519 moderate serious Thyroiditis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
0.74 [0.10 ; 5.26 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 4 0% 2,445 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.32 [0.01; 9.50]
CheckMate 026 (PDL1>1%), 2016 0.10 [0.01; 1.78]
CheckMate 9LA, 2021 1.17 [0.35; 3.88]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.06; 15.71]
KEYNOTE-042 (PDL1>1%), 2019 0.24 [0.01; 5.36]
MYSTIC (D ; all population), 2020 0.07 [0.00; 1.18]
MYSTIC (DT ; all population), 2020 0.07 [0.00; 1.18]
0.36 [0.13 ; 1.01 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 7 19% 4,519 moderate serious Weight decreased TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
KEYNOTE-407, 2018 10.24 [0.56; 188.30]
5.05 [0.55 ; 46.09 ] EMPOWER lung1 (all population), 2021, KEYNOTE-407, 2018 2 0% 1,255 low not evaluable Acute kidney injury AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
0.24 [0.01 ; 5.34 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Alopecia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
KEYNOTE-407, 2018 0.33 [0.03; 3.22]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.42 [0.09 ; 1.95 ] EMPOWER lung1 (all population), 2021, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 4 0% 2,699 moderate not evaluable Anaemia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.03 [0.01; 0.13]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.08 [0.03; 0.20]
KEYNOTE-189, 2018 1.07 [0.67; 1.71]
KEYNOTE-407, 2018 0.72 [0.46; 1.11]
MYSTIC (D ; all population), 2020 0.16 [0.07; 0.34]
MYSTIC (DT ; all population), 2020 0.12 [0.05; 0.28]
0.20 [0.08 ; 0.55 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 92% 3,855 moderate serious Arthralgia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
KEYNOTE-407, 2018 2.03 [0.37; 11.17]
1.52 [0.33 ; 6.97 ] EMPOWER lung1 (all population), 2021, KEYNOTE-407, 2018 2 0% 1,255 low not evaluable Asthenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.36 [0.07; 1.89]
KEYNOTE-189, 2018 1.83 [0.78; 4.31]
KEYNOTE-407, 2018 0.60 [0.21; 1.66]
MYSTIC (D ; all population), 2020 0.95 [0.41; 2.23]
MYSTIC (DT ; all population), 2020 0.86 [0.36; 2.05]
0.93 [0.61 ; 1.43 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 3,855 moderate not evaluable Back pain AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
MYSTIC (D ; all population), 2020 0.32 [0.03; 3.05]
MYSTIC (DT ; all population), 2020 0.63 [0.10; 3.80]
0.48 [0.13 ; 1.77 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Blood creatinine increased AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Colitis AE (grade 3-4)detailed results KEYNOTE-407, 2018 2.04 [0.50; 8.23]
2.04 [0.50 ; 8.23 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Constipation AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
KEYNOTE-189, 2018 2.00 [0.22; 18.06]
KEYNOTE-407, 2018 0.67 [0.11; 4.04]
MYSTIC (D ; all population), 2020 0.95 [0.06; 15.31]
MYSTIC (DT ; all population), 2020 1.90 [0.17; 21.07]
1.21 [0.48 ; 3.01 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 3,855 moderate not evaluable Cough AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.84 [0.06; 55.14]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
KEYNOTE-407, 2018 0.67 [0.11; 4.04]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.90 [0.25 ; 3.23 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 5 0% 3,158 low not evaluable Decreased appetite AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.06; 15.46]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-189, 2018 3.02 [0.36; 25.28]
KEYNOTE-407, 2018 1.21 [0.37; 4.02]
MYSTIC (D ; all population), 2020 1.44 [0.40; 5.14]
MYSTIC (DT ; all population), 2020 1.43 [0.40; 5.11]
1.49 [0.78 ; 2.85 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 3,855 moderate not evaluable Diarrhoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.16 [0.02; 1.32]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.01; 5.09]
KEYNOTE-189, 2018 1.79 [0.71; 4.50]
KEYNOTE-407, 2018 1.88 [0.69; 5.16]
MYSTIC (D ; all population), 2020 0.38 [0.07; 1.96]
MYSTIC (DT ; all population), 2020 2.12 [0.73; 6.17]
1.08 [0.51 ; 2.29 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 44% 3,855 moderate serious Dyspnoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.17; 21.41]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-189, 2018 0.67 [0.30; 1.48]
KEYNOTE-407, 2018 3.04 [0.31; 29.44]
MYSTIC (D ; all population), 2020 1.61 [0.58; 4.47]
MYSTIC (DT ; all population), 2020 1.11 [0.37; 3.33]
1.10 [0.66 ; 1.84 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 3,855 moderate serious Epistaxis AE (grade 3-4)detailed results KEYNOTE-407, 2018 1.01 [0.02; 50.94]
1.01 [0.02 ; 50.94 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-05 11:10 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743
